Eli Lilly and Company $LLY Shares Acquired by Allen Investment Management LLC

Allen Investment Management LLC increased its holdings in Eli Lilly and Company (NYSE:LLY) by 29.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 8,541 shares of the company’s stock after purchasing an additional 1,936 shares during the quarter. Allen Investment Management LLC’s holdings in Eli Lilly and Company were worth $9,178,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after purchasing an additional 1,006,885 shares in the last quarter. State Street Corp lifted its holdings in Eli Lilly and Company by 0.6% in the third quarter. State Street Corp now owns 34,726,558 shares of the company’s stock worth $26,496,364,000 after purchasing an additional 219,590 shares during the period. Capital Research Global Investors grew its position in Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after buying an additional 4,332,008 shares in the last quarter. Wellington Management Group LLP increased its stake in Eli Lilly and Company by 4.1% during the 3rd quarter. Wellington Management Group LLP now owns 14,563,780 shares of the company’s stock valued at $11,112,164,000 after buying an additional 574,229 shares during the period. Finally, Norges Bank acquired a new position in Eli Lilly and Company during the 4th quarter valued at about $12,976,634,000. Institutional investors own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly reported strong Phase 3 data for Retevmo (selpercatinib), showing an 83% reduction in the risk of disease recurrence or death in early-stage RET fusion-positive lung cancer, a result that could support a broader label and future revenue growth. Article Title
• Positive Sentiment: The company also signed new licensing and collaboration deals with Hanmi and Haisco, extending its innovation pipeline and signaling continued deal-making momentum in Asia. Article Title
• Positive Sentiment: Camurus said Lilly exercised an option in their cardiometabolic drug collaboration, extending another pipeline partnership and adding to investor confidence in Lilly’s long-term growth strategy. Article Title
• Positive Sentiment: Market commentary remained bullish after CEO David Ricks’ remarks about Lilly’s hot product lineup, while social sentiment and analyst coverage continued to highlight the company as one of the market’s leading growth names. Article Title
• Neutral Sentiment: Some articles framed Lilly as one of the top stocks to watch, but these pieces were mostly commentary rather than new company-specific catalysts. Article Title
• Negative Sentiment: Despite the positive news, LLY has been trading lower recently, and some market attention appears to reflect profit-taking after a strong run and valuation concerns rather than a deterioration in fundamentals. Article Title
• Negative Sentiment: Competitive pressure in the GLP-1 market remains a risk, as Novo Nordisk’s oral Wegovy pill is still outperforming Lilly’s rival tablet, even though growth is slowing. Article Title

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Scotiabank reaffirmed an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Jefferies Financial Group lifted their price target on Eli Lilly and Company from $1,300.00 to $1,330.00 in a research report on Thursday, May 21st. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Morgan Stanley reaffirmed an “overweight” rating and set a $1,344.00 target price on shares of Eli Lilly and Company in a report on Friday, May 1st. Finally, Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research report on Thursday, February 19th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company Stock Down 2.3%

Shares of NYSE:LLY opened at $1,079.96 on Tuesday. The firm has a 50 day simple moving average of $959.18 and a 200 day simple moving average of $1,010.74. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,149.10. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The company has a market cap of $1.02 trillion, a PE ratio of 38.36, a price-to-earnings-growth ratio of 1.21 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s payout ratio is 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.